Recent News

• 20 April 2026   Press Release

  Enamine Strengthens Its Sustainable Procurement Program in 2026

  In 2026, Enamine’s Sustainable Procurement Program is reaching a new level of maturity and impact. Building on many years of close cooperation with suppliers – and reinforced by global best practices – the Company is further strengthening its approach to responsible and sustainable procurement across the entire supply chain.

• 07 April 2026   Press Release

  Chemspace, Enamine, and Paul Scherrer Institute Launch a Joint Service for Fragment-Based Lead Discovery

  Chemspace, a drug discovery engine providing machine learning-guided support for hit identification, hit to lead, and lead optimization using the largest purchasable collection of chemicals and biologics, Enamine, a leading provider of small molecules and drug discovery services, and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, have announced today a strategic collaboration aimed at creating an efficient platform for fragment-based drug discovery in the ultra-large chemical space.

• 02 April 2026   Press Release

  Enamine's IDD Platform Accelerates Nuclide Therapeutics' Precision Radiotheranostics Pipeline Towards the Clinic

  Nuclide Therapeutics and Enamine initiated their cooperation in 2025. Since then, Enamine has supported Nuclide Therapeutics in progressing from preclinical evaluation towards IND-enabling studies and first-in-human clinical trials for its lead program focused on first-in-class molecular radiotherapies for therapy-resistant cancers. The relationship proved to be highly productive and innovative, delivering development milestones ahead of schedule with short development cycles and efficient use of resources.